S100A4 and posterior cortical atrophy: 11 In patients it was described as potential biomarker in plasma and biopsy samples68,69 and anti-S100A4 antibody therapy had a positive effect of PCa treatment in a mouse model.69 An additional cancer-associated target found at higher levels after sEV treatment was β-catenin.